StudyFinder
Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

32 Study Matches

THE MAGENTA ELEVATE HIGH-RISK PCI PIVOTAL TRIAL PROTOCOL (ELEVATE III)

For patients having a procedure to open severe blockages in the heart's arteries. Due to your severe blockages and weakened heart function, you may be at higher risk of having a drop in blood flow. THE MAGENTA ELEVATE device heart pump device is used during the procedure. This device is intended to prevent drops in blood flow during the procedure. It does this by assisting the heart in pumping blood through the body.

Contact(s):

MICHELLE BUTCHER - MBUTCHE1@HFHS.ORG

Principal Investigator: Mir Babar Basir
Principal Investigator ID: mbasir1@hfhs.org
Sex: Male or Female
Age: 18 years and over
Phase: N/A
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Heart function less than 50%. Participant signed the informed consent. Additional criteria will be assessed prior to enrollment.
Exclusion Criteria:
You may not participate IF: 1. Age less than 18 and greater than 89 years old. 2. Cardiac arrest or Cardiogenic shock 3. Prior stroke or TIA within 3 months prior to enrollment. 4. Participant is presently or has recently been intubated. Additional criteria will be assessed prior to enrollment.
Interventions: Drug/Device: The Magenta Elevate? System
Conditions: HIGH RISK PCI, CAD, CORONARY STENOSIS
Keywords: CAD, CARDIAC CATHETERIZATION, CORONARY STENOSIS, PCI

Further Actions

I'm interested
Share via email
See this study on ClinicalTrials.gov

Randomized Evaluation of Bromocriptine in Myocardial Recovery Therapy (REBIRTH) for Peripartum Cardiomyopathy

Peripartum cardiomyopathy (PPCM) is a rare type of heart failure that can happen during the last month of pregnancy or within five months after giving birth, causing the heart to weaken and not pump blood well. Many women improve with heart failure treatment. This study is testing whether bromocriptine, a drug approved in the U.S. for other conditions but not PPCM, can help improve heart function in women recently diagnosed with PPCM.

Contact(s):

Jodi Carter - Jcarte23@hfhs.org

Principal Investigator: Ryhm Radjef
Principal Investigator ID: rradjef1@hfhs.org
Sex: Female
Age: 18 years and over
Phase: IV
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• New diagnosis of peripartum cardiomyopathy
• Post-delivery and within the first 5 months post-partum
Exclusion Criteria:

• Previous diagnosis of heart disease (prior to pregnancy)
Interventions: Drug/Device: Bromocriptine
Conditions: Peripartum or Postpartum Cardiomyopathy
Keywords: cardiomyopathy, heart failure, Peripartum, postpartum

Further Actions

I'm interested
Share via email
See this study on ClinicalTrials.gov